ArticleCancers2022
Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06065007 (Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Trial
- SuperRCA assay ofThe journal of allergy and clinical immunology. Global · 2026Article
- Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.The journal of allergy and clinical immunology. Global · 2026Article
- Hereditary alpha-tryptasemia demonstrates relative basophil enrichment without signs of cellular hyperreactivity.The journal of allergy and clinical immunology. Global · 2026Article
- Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.Blood advances · 2026Article
- Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.Clinical reviews in allergy & immunology · 2026Review
- Hereditary Alpha-Tryptasemia and Mastocytosis: What We Know and What We Need To Learn.Current allergy and asthma reports · 2026Review
- Management of skeletal-related events and fracture prevention in systemic mastocytosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Advances in the Management of Mediator-Related Symptoms in Non-Advanced Systemic Mastocytosis.ImmunoTargets and therapy · 2026Review
- Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study.British journal of haematology · 2025Article
- The evaluation, management, and future of indolent systemic mastocytosis.Annals of hematology · 2025Review
- Article
- Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study.European journal of epidemiology · 2025Article
- Utility of tryptase genotyping in the screening, diagnosis, and management of systemic mastocytosis.Frontiers in allergy · 2025Review
- Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report.Case reports in hematology · 2025Article
- MASTering systemic mastocytosis: Lessons learned from a large patient cohort.The journal of allergy and clinical immunology. Global · 2024Article
- Epidemiology of mastocytosis: a population-based study (Sweden).Acta oncologica (Stockholm, Sweden) · 2024Article
- Using the Right Criteria for MCAS.Current allergy and asthma reports · 2024Review
- A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.Diagnostics (Basel, Switzerland) · 2023Review
- Comprehensive mastocytosis data analysis from a single center.BMC cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Systemic mastocytosis (SM) is a rare, clonal, clinically heterogeneous disorder of the mast cells (MCs), and mainly affects adults. The present study aims to describe the clinical and laboratory features as well as the outcomes of SM. A 15-year retrospective study was conducted on 195 consecutive SM patients (aged ≥ 18 years) diagnosed in 2006−2020 at the Multidisciplinary Mastocytosis Center at Karolinska University Hospital. Patients with indolent SM (ISM) represented the most common SM variant (88.2%). Furthermore, the frequencies of aggressive SM and SM with associated non-mast-cell hematological neoplasm were 4.1% and 7.7%, respectively. The prevalence of SM in the adult population of the Stockholm region was estimated to be 10.6/100,000 inhabitants, and the mean incidence of SM cases in the Stockholm region was 0.77/100,000 people per year. In this series, tryptase levels were below 20 ng/mL in 51 patients (26%). Osteoporosis was present in 21.9% of all cases. Interestingly, there was no progression from ISM to advanced SM variants in our study. Furthermore, overall survival was significantly better in ISM patients compared to advanced SM patients (p < 0.0001). Our data suggest that the early recognition and correct diagnosis of SM has prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.